CClinicalTrials.gg
Not yet recruitingNCT06152796Updated Dec 1, 2023

Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus

A Phase 2 interventional study of Paracetamol and Ibuprofen in Patent Ductus Arteriosus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 28 Weeks to 37 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Assiut University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
28 Weeks to 37 Weeks
Sex
All
01

Study summary

To compare efficacy and safety of paracetamol and ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in preterm infants.

Read the detailed description

The ductus arteriosus (DA) is an essential fetal blood vessel that connects the pulmonary artery to the aorta and serves to shunt blood away from the lungs into the umbilical placental circulation where gas exchange takes place.At birth, closure of the DA is a critical event in the transition to the postnatal circulatory pattern. However, there are situations in which DA closure does not occur or is delayed, resulting in the condition known as persistent patent DA (PDA) .

After birth, it usually closes within 48 h. A persistently PDA is diagnosed when the DA fails to close after 72 h.

PDA accounts for 5% to 10% of all congenital heart diseases. However, the incidence surges up to 60% in preterm infants and is inversely related to gestational age(GA) and birth weight.

The closure of the DA in full-term infants occurs in two steps. Initially, within the first few hours after birth,increased arterial PaO2 and decreased circulating prostaglandins allow the smooth muscle media of the ductus to constrict. As a result of the constriction, the inner muscle wall of the DA develops profound ischemic hypoxia which leads to the formation of vascular endothelial growth factor, transforming growth factor beta,and other inflammatory mediators and growth factors that transform the ductus into a non-contractile ligament.

The clinical consequences of PDA are related to the degree of left- to-right shunting through the PDA, with its associated change in blood flow to the lungs, kidneys, and intestine . This results in increased pulmonary blood flow and increased incidence of further comorbidities such as chronic lung disease, intraventricular hemorrhage(IVH), necrotizing enterocolitis (NEC), and retinopathy.Therefore, closure of the PDA is essential to prevent these complications and to improve both cardiorespiratory status and survival rate .

Clinical criteria of hemodynamically significant PDA (hs-PDA) are the following: tachycardia,bounding pulse with wide pulse pressure, hyperdynamic precordium with continuous murmur on auscultation, hepatomegaly, edema, unexplained metabolic acidosis, failure of respiratory distress syndrome to improve at 2-7 days, and unexplained CO2 retention in mechanically ventilated neonates.

Echocardiography has been examined in multiple studies as an objective measure of hs-PDA.Echocardiographic criteria of hs-PDA are the following: left atrial dilatation (left atrial: aortic root >1.6), diastolic turbulence (backflow) on Doppler in the pulmonary artery, internal diameter of duct >1.5 mm, and reverse end diastolic flow in the descending aorta/mesenteric artery .

Treatment options for hs-PDA include conservative management, pharmacologic interventions, surgical ligation, and a transcatheter approach to ductal closure. However, a consensus on PDA management strategies remains elusive. Surgical ligation is usually considered when other medical treatments have either failed or were contraindicated.

For this purpose, the first-line therapy is medical and nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs of choice, preventing the conversion of arachidonic acid into prostaglandins via cyclooxygenase (COX) inhibition, in both the existing isoforms COX-1 (constitutive) and COX-2 (inducible) . Reduction in prostaglandin levels leads to DA muscular wall constriction through the hypoxia of ductal vasa vasorum and consequent local angiogenesis, formation of neointimal tissue, and apoptosis. These mechanisms, in conjunction with platelet recruitment and activation, lead to processes of obstruction and fibrosis and, as a result, anatomical ductal closure .

Ibuprofen, a non-steroidal anti-inflammatory drug, inhibits both cyclooxygenase-1 and cyclooxygenase-2, which are enzymes necessary for the conversion of arachidonic acid to various prostaglandins among them PGE2.Unlike ibuprofen, paracetamol is thought to act on prostaglandin synthase at the peroxidase region of the enzyme.The role of paracetamol as an alternative treatment for the closure of hsPDA has gained attention because of the potential side-effects of cyclooxygenase inhibitors.

Studies comparing oral paracetamol versus oral ibuprofen in PDA closure reported that oral paracetamol and ibuprofen were similarly effective for the closure of PDA.While,El-Farrash et al. demonstrated that oral paracetamol is an effective and well-tolerated, first line drug treatment of PDA that was comparable to ibuprofen in terms of the rate of ductal closure and even showed decreased LPA, RVSP and LA/Ao ratio.Also,Al-Shaibi et al. documented that oral paracetamol was between cost-effective and dominant over both oral and IV ibuprofen formulations.However, another study done by Roofthooft et al.showed disappointing results with IV paracetamol administration, as PDA closure was reported in only 18% of the patients with relatively low gestational age.

Regarding the drug safety profile,Oncel et al.and Dang et al.reported that both drugs were tolerated and deemed safe in terms of renal and liver variables, as well as a lack of statistically significant difference in major complications(NEC,IVH,bronchopulmonary dysplasia).However,Balachander et al. Revealed Incidence of AKI is significantly lower with paracetamol as compared to ibuprofen.Also, Hammerman et al. reported that paracetamol could offer important therapeutic advantages over NSAIDs (e.g., indomethacin and ibuprofen), as paracetamol has no peripheral vasoconstrictive effect and can be given to infants with clinical contraindications to NSAIDs.

The availability of different management options poses a challenge for neonatologists when making evidence-based management decisions after diagnosing hemodynamically significant PDAs. The dilemma is whether to use pharmacotherapy at all, and if a decision is made to treat the PDA medically, what should be the ideal choice of pharmacotherapy.

02

Conditions studied

  • Patent Ductus Arteriosus
03

In context

Ductus Arteriosus, Patent

144 studies on the registry are indexed under Ductus Arteriosus, Patent; 17 are open to participants now.

This study's planned enrollment of 56 is below the median of 80 across 81 interventional studies indexed under Ductus Arteriosus, Patent.

Browse Ductus Arteriosus, Patent studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 37 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • preterm infants
  • with gestational age ≤37weeks
  • who had echocardiographically confirmed significant PDA.

Exclusion criteria

Exclusion Criteria:

  • Preterm neonates
  • with major congenital anomalies,
  • life threatening sepsis,
  • NEC,
  • IVH,
  • urine output \<1ml/kg/h in the last 24 h,
  • serum creatinine concentration >1.5 mg/dl, -platelet count \<100,000/ml,
  • complex congenital heart,
  • or duct-dependent lesions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Paracetamol

    preterms receive oral/iv paracetamol at the dose of 15 mg/kg every 6 h for 3 days.

    Drug: Paracetamol

  • Experimental
    Ibuprofen

    preterms receive oral ibuprofen at the initial dose 10 mg/kg, followed by 5 mg/kg after 24 and 48 h

    Drug: Ibuprofen

Interventions

  • DrugParacetamol

    Anti_inflammatory drug

  • DrugIbuprofen

    Non steroidal anti_inflammatory drug

06

What researchers measure

Primary outcomes

  1. Closure of PDA

    Echo confirmed closure

    Time frame: 6 days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06152796
Lead sponsor
Assiut University
Responsible party
Nada Abdelfatah Abdelaal Abdelsamie (Doctor, Assiut University) — Principal investigator
First posted
Dec 1, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Sep 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Dec 1, 2023

Study contacts

Nada Abdelfatah Abdelaal
Contact
nadaabdelfatah4@gmail.com
01023085851
El-Sayed Khalil Abdel-karim, professor
Contact
Khalilsay53@aun.edu.eg
01060805170

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion